Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Sees Large Drop in Short Interest

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) was the recipient of a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 400 shares, a decline of 86.2% from the January 15th total of 2,900 shares. Based on an average trading volume of 14,500 shares, the days-to-cover ratio is presently 0.0 days.

Scinai Immunotherapeutics Price Performance

Shares of Scinai Immunotherapeutics stock opened at $3.24 on Friday. The firm has a fifty day simple moving average of $3.47 and a 200-day simple moving average of $3.57. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.16 and a current ratio of 1.16. Scinai Immunotherapeutics has a 1-year low of $2.23 and a 1-year high of $8.92.

Scinai Immunotherapeutics (NASDAQ:SCNI) last announced its quarterly earnings results on Friday, November 22nd. The company reported $8.40 earnings per share (EPS) for the quarter.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.